The Cost-Effectiveness of Ranibizumab for the Treatment of Diabetic Macular Edema

Purpose To assess the incremental, comparative effectiveness (patient value gain) and cost effectiveness (financial value gain) associated with 0.3-mg intravitreal ranibizumab injection therapy versus sham therapy for diabetic macular edema (DME). Design Value-Based Medicine (Center for Value-Based...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Ophthalmology (Rochester, Minn.) Minn.), 2015-07, Vol.122 (7), p.1416-1425
Hauptverfasser:	Brown, Gary C., MD, MBA, Brown, Melissa M., MD, MBA, Turpcu, Adam, PhD, Rajput, Yamina, PhD
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Angiogenesis Inhibitors - adverse effects Angiogenesis Inhibitors - economics Angiogenesis Inhibitors - therapeutic use Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - economics Antibodies, Monoclonal, Humanized - therapeutic use Cost-Benefit Analysis Diabetic Retinopathy - drug therapy Diabetic Retinopathy - economics Female Health Care Costs Humans Intravitreal Injections Macular Edema - drug therapy Macular Edema - economics Male Middle Aged Ophthalmology Quality of Life Quality-Adjusted Life Years Randomized Controlled Trials as Topic Ranibizumab Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity - drug effects Visual Acuity - physiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!